Jonathan Rayment

Has grant

Clinical Assistant Professor

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Antibiotic Treatment of Staphylococcus aureus in Stable Patients with CF (ASAP-CF)

Open Date: 2019-03-01

Close Date: 2022-02-28

Grant: Close

Structural and Functional MRI Assessment of Treatment Response in Early Cystic Fibrosis Lung Disease

Open Date: 2017-04-01

Close Date: 2022-03-31

Grant: Close

The Role of Integrin-Linked Kinase in the Induction and Progression of Mammary Epithelial Tumourigenesis

Open Date: 2006-09-01

Close Date: 2006-09-30

Grant: Close

The Role of Integrin Signal Transduction in Mammary Tumorigenesis

Open Date: 2004-10-01

Close Date: 2005-09-01

Articles (17)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (11)

Kirk Schultz

Professor

The University of British Columbia

CANADA

View details

Kim G. Nielsen

DENMARK

View details

Niranjan Kissoon

Professor

The University of British Columbia

CANADA

View details

Taneille Johnson

Paediatric Intensivist, Assistant Professor of Paediatrics

Western University

CANADA

View details

William A. Gower

UNITED STATES

View details

David M. Goldfarb

The University of British Columbia

CANADA

View details

Dewi Schrader

Clinical Assistant Professor, Paediatric Neurologist

CANADA

View details

Kevin Harris

Associate Professor

The University of British Columbia

CANADA

View details

Anne Stone

Associate Professor

Oregon Health & Science University

UNITED STATES

View details

Claire Hogg

Professor in Practice, paediatric Respiratory medicine

UNITED KINGDOM

View details

Susanna A. McColley

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonathan Rayment

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (17)

Frequent microbiological surveillance during inpatient cystic fibrosis pulmonary exacerbations has limited clinical value

Detection of Bronchiolitis Obliterans Syndrome after Pediatric Hematopoietic Stem Cell Transplantation: An Official American Thoracic Society Clinical Practice Guideline

A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment

Multiple breath washout and oscillometry after allogenic HSCT: a scoping review

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective

Genetics of bronchopulmonary dysplasia: An update

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged >6 Years with Cystic Fibrosis and at Least One F508del Allele A Phase 3, Open-Label Clinical Trial

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

All hands on deck: A multidisciplinary approach to SARS-CoV-2-associated MIS-C

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis

Heterogenous Disease Course and Long-Term Outcome of Children's Interstitial Lung Disease Related to Filamin A Gene Variants

Multiple Breath Washout Testing to Identify Pulmonary Chronic Graft Versus Host Disease in Children After Hematopoietic Stem Cell Transplantation

Pulmonary functional MRI: Detecting the structure–function pathologies that drive asthma symptoms and quality of life

The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial

A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele

Collaborators (11)

Kirk Schultz

Kim G. Nielsen

Niranjan Kissoon

Taneille Johnson

William A. Gower

David M. Goldfarb

Dewi Schrader

Kevin Harris

Anne Stone

Claire Hogg

Susanna A. McColley

Make your next move.

Jonathan Rayment

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (17)

Frequent microbiological surveillance during inpatient cystic fibrosis pulmonary exacerbations has limited clinical value

Detection of Bronchiolitis Obliterans Syndrome after Pediatric Hematopoietic Stem Cell Transplantation: An Official American Thoracic Society Clinical Practice Guideline

A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment

Multiple breath washout and oscillometry after allogenic HSCT: a scoping review

Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective

Genetics of bronchopulmonary dysplasia: An update

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged &gt;6 Years with Cystic Fibrosis and at Least One F508del Allele A Phase 3, Open-Label Clinical Trial

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

All hands on deck: A multidisciplinary approach to SARS-CoV-2-associated MIS-C

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis

Heterogenous Disease Course and Long-Term Outcome of Children's Interstitial Lung Disease Related to Filamin A Gene Variants

Multiple Breath Washout Testing to Identify Pulmonary Chronic Graft Versus Host Disease in Children After Hematopoietic Stem Cell Transplantation

Pulmonary functional MRI: Detecting the structure–function pathologies that drive asthma symptoms and quality of life

The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial

A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele

Collaborators (11)

Kirk Schultz

Kim G. Nielsen

Niranjan Kissoon

Taneille Johnson

William A. Gower

David M. Goldfarb

Dewi Schrader

Kevin Harris

Anne Stone

Claire Hogg

Susanna A. McColley

Make your next move.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged >6 Years with Cystic Fibrosis and at Least One F508del Allele A Phase 3, Open-Label Clinical Trial